SCHEMBL4024922

SCHEMBL4024922

O=c1c(NCc2ccc(-c3ccccc3)cc2)c(Nc2cccnc2)c1=O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.61
CHEK2 O96017 6/20 0.52
PRKACA P17612 6/20 0.52
RPS6KB1 P23443 6/20 0.52
GSK3A P49840 6/20 0.52
GSK3B P49841 6/20 0.52
RPS6KA3 P51812 6/20 0.52
ROCK1 Q13464 6/20 0.52
PRKG1 Q13976 6/20 0.52
PKN2 Q16513 6/20 0.52
CDC42BPA Q5VT25 6/20 0.52
HIPK4 Q8NE63 6/20 0.52
AURKB Q96GD4 6/20 0.52
CSNK1G3 Q9Y6M4 6/20 0.52
CHEK1 O14757 5/20 0.52
MKNK2 Q9HBH9 5/20 0.52
SGK2 Q9HBY8 5/20 0.52
CLK4 Q9HAZ1 5/20 0.52
AKT1 P31749 5/20 0.52
NEK4 P51957 4/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4028084 0.86 FLT4 (0.60) MAPKAPK2CHEK2PRKACARPS6KB1GSK3A
SCHEMBL19198714 0.82 RAB9A (0.69) CLK4RAB9ALTA4HKDM4CKDM5B
SCHEMBL30520150 0.82 RAB9A (0.69) CLK4RAB9ALTA4HKDM4CKDM5B
SCHEMBL4026559 0.80 GSK3A (0.62) MAPKAPK2CHEK2PRKACARPS6KB1GSK3A
SCHEMBL4024933 0.77 CHEK1 (0.59) MAPKAPK2CHEK2PRKACARPS6KB1GSK3A
SCHEMBL4375983 0.76 MAPKAPK2 (1.00) MAPKAPK2CHEK2PRKACARPS6KB1GSK3A
SCHEMBL25366208 0.76 HDAC6 (0.64)
SCHEMBL29376758 0.76 HDAC6 (0.64)
SCHEMBL4027877 0.75 FES (0.77) MAPKAPK2FLT4RAB9AKDM4CMAPK1
SCHEMBL7350556 0.74 MAPKAPK2 (0.43) MAPKAPK2CHEK2PRKACARPS6KB1GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450348-B2 Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects FORMA TM, LLC (US) 2013-05-28 US disclosed
EP-2096107-A1 Derivatives of squaric acid with anti-proliferative activity GPC Biotech AG (DE) 2009-09-02 EP disclosed
EP-1674457-B1 Derivatives of squaric acid with anti-proliferative activity GPC BIOTECH AG (DE) 2009-06-03 EP disclosed
US-20080200523-A1 Derivatives of squaric acid with anti-proliferative activity Valo Health, LLC 2008-08-21 US disclosed
EP-1674457-A1 Derivatives of squaric acid with anti-proliferative activity GPC Biotech AG (DE) 2006-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200523-A1 Derivatives of squaric acid with anti-proliferative activity SQLE, FDFT1, DLD MAPKAPK2 1940/4885CHEK2 2740/4885PRKACA 4333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.